Eleonora Scorletti
Eleonora Scorletti
Verified email at
Cited by
Cited by
Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease
E Scorletti, CD Byrne
Annual review of nutrition 33, 231-248, 2013
Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study
E Scorletti, L Bhatia, KG McCormick, GF Clough, K Nash, L Hodson, ...
Hepatology 60 (4), 1211-1221, 2014
Complications, morbidity and mortality of nonalcoholic fatty liver disease
A Mantovani, E Scorletti, A Mosca, A Alisi, CD Byrne, G Targher
Metabolism 111, 154170, 2020
Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents
A Mosca, V Nobili, R De Vito, A Crudele, E Scorletti, A Villani, A Alisi, ...
Journal of hepatology 66 (5), 1031-1036, 2017
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial
E Scorletti, AL West, L Bhatia, SP Hoile, KG McCormick, GC Burdge, ...
Journal of hepatology 63 (6), 1476-1483, 2015
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
E Scorletti, CD Byrne
Molecular aspects of medicine 64, 135-146, 2018
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
E Scorletti, PC Calder, CD Byrne
Endocrine 40 (3), 332-343, 2011
Nonalcoholic fatty liver disease in children
JP Mann, L Valenti, E Scorletti, CD Byrne, V Nobili
Seminars in liver disease 38 (01), 001-013, 2018
Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
CD Byrne, J Patel, E Scorletti, G Targher
Bmj 362, 2018
Diagnosis and management of non-alcoholic fatty liver disease
E Jennison, J Patel, E Scorletti, CD Byrne
Postgraduate medical journal 95 (1124), 314-322, 2019
Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease
E Scorletti, PR Afolabi, EA Miles, DE Smith, A Almehmadi, A Alshathry, ...
Gastroenterology 158 (6), 1597-1610. e7, 2020
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized …
A Mantovani, CD Byrne, E Scorletti, CS Mantzoros, G Targher
Diabetes & metabolism 46 (6), 427-441, 2020
Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression
L Bhatia, E Scorletti, N Curzen, GF Clough, PC Calder, CD Byrne
Atherosclerosis 246, 13-20, 2016
Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
L Hodson, L Bhatia, E Scorletti, DE Smith, NC Jackson, ...
European journal of clinical nutrition 71 (8), 973-979, 2017
Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty …
E Scorletti, L Bhatia, KG McCormick, GF Clough, K Nash, PC Calder, ...
Contemporary clinical trials 37 (2), 301-311, 2014
Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
V Nobili, A Alisi, G Musso, E Scorletti, PC Calder, CD Byrne
Critical reviews in clinical laboratory sciences 53 (2), 106-120, 2016
Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D3 Levels
G Targher, E Scorletti, A Mantovani, CD Byrne
Metabolic Syndrome and Related Disorders 11 (4), 217-228, 2013
Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD
V Nobili, A Alisi, A Mosca, C Della Corte, S Veraldi, R De Vito, ...
Liver International 38 (2), 342-349, 2018
Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis
P Wainwright, E Scorletti, CD Byrne
Current diabetes reports 17 (4), 1-8, 2017
Extrahepatic diseases and NAFLD: the triangular relationship between NAFLD, type 2-diabetes and dysbiosis
E Scorletti, CD Byrne
Digestive Diseases 34 (Suppl. 1), 11-18, 2016
The system can't perform the operation now. Try again later.
Articles 1–20